NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC

Matrisome Bio seeks to develop novel, safe and effective therapeutic and diagnostic modalities against the rare metastatic cancer, Hereditary Breast- and Ovarian-cancer (HBOC), by targeting disease-specific components of the extracellular matrix (ECM). HBOC patients are currently facing a poor prognosis and a high risk of developing metastatic disease that is neither effectively diagnosed nor treated by currently available approaches. Targets in the ECM are expressed in primary tumors as well as disseminated metastases and are largely unexplored relative to tumor cell-associated antigens. Matrisome Bio is pursuing disease-specific ECM proteins that were shown to be widely expressed in HBOC tumors and offer great potential for the development of targeted cancer therapeutics to deliver anti-cancer payloads and enable diagnostic imaging of both primary tumors and metastases. Matrisome Bio seeks to develop a proof-of-concept theranostic radiopharmaceutical compound directed to a disease-specific ECM target known to be expressed in tumor tissues of HBOC patients. This compound has the potential to be developed into a first-in-class theranostic that can be administered systemically, reach solid tumors as well as small metastases, and change the paradigm of both, treatment and diagnosis, for women suffering from HBOC disease. Project Number: 75N91025C00039-0-9999-1 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Institution: MATRISOME BIO, INC., Cambridge, MA | Award Amount: $354,456 | Activity Code: N43 View on NIH RePORTER: https://reporter.nih.gov/project-details/11416590